Home > Insider Trading > Filing (0001012975-17-000071)

Filing Details

Accession Number:: 0001012975-17-000071
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-01-31 16:20:33
Reporting Period:: 2017-01-31

Filing Date:: 2017-01-31
Accepted Time:: 2017-01-31 16:20:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1370053	Anaptysbio Inc	ANAB	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1018534	D Alan Frazier	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1344203	J Nader Naini	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1365617	J Patrick Heron	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1531105	R Nathan Every	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1553071	Frazier Healthcare Vii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1575192	Frazier Healthcare Vii-A, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1654631	Fhm Vii, L.l.c.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1654632	Fhm Vii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-01-31	1,428,571	$0.00	1,428,571	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2017-01-31	604,055	$0.00	604,055	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2017-01-31	195,751	$0.00	195,751	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2017-01-31	733,740	$0.00	733,740	No	4	C	Direct
Common Stock	Acquisiton	2017-01-31	209,095	$0.00	209,095	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2017-01-31	311,291	$15.00	311,291	No	4	P	Direct
Common Stock	Acquisiton	2017-01-31	88,709	$15.00	88,709	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Direct
No	4	C	Indirect	See footnote
No	4	P	Direct
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2017-01-31	1,428,571	$0.00	1,428,571	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-01-31	604,055	$0.00	604,055	$0.00
Common Stock	Series C-1 Preferred Stock	Disposition	2017-01-31	195,751	$0.00	195,751	$0.00
Common Stock	Series D Preferred Stock	Disposition	2017-01-31	733,740	$0.00	733,740	$0.00
Common Stock	Series D Preferred Stock	Disposition	2017-01-31	209,095	$0.00	209,095	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect

Footnotes

The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.